Back

prof. dr. J.G.J. (Jan) van de Winkel

prof. dr. J.G.J. (Jan) van de Winkel

Full Professor

Show full profile

Research Output (250)

Human kappa light chain targeted Pseudomonas exotoxin A--identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development

Kellner C., Bleeker W.K., Lammerts van Bueren J.J., Staudinger M., Klausz K., Derer S., Glorius P., Muskulus A., de Goeij B.E.C.G., van de Winkel J.G.J., Parren P.W.H.I., Valerius T., Gramatzki M., Peipp M. 2011, In: Journal of Immunological Methods. 371 , p. 122-133 12 p.

Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry

Rose R.J., Labrijn A.F., van den Bremer E.T.J., Loverix S., Lasters I., van Berkel P.H.C., van de Winkel J.G.J., Schuurman J., Parren P.W.H.I., Heck A.J.R. 2011, In: Structure. 19 , p. 1274-1282 9 p.

Penetration of antibody-opsonized cells by the membrane attack complex of complement promotes Ca(2+) influx and induces streamers

Beum P.V., Lindorfer M.A., Peek E.M., Stukenberg P.T., de Weers M., Beurskens F.J., Parren P.W.H.I., van de Winkel J.G.J., Taylor R.P. 2011, In: European Journal of Immunology. 41 , p. 2436-2446 11 p.

Molecular engineering to improve antibodies' anti-lymphoma activity

Peipp M., van de Winkel J.G.J., Valerius T. 2011, In: Best practice & Research. Clinical Haematology. 24 , p. 217-29 13 p.

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

de Weers M., Tai Y-T, van der Veer M.S., Bakker J.M., Vink T., Jacobs D.C.H., Oomen L.A., Peipp M., Valerius T., Slootstra J.W., Mutis T., Bleeker W.K., Anderson K.C., Lokhorst H.M., van de Winkel J.G.J., Parren P.W.H.I. 2011, In: Journal of Immunology. 186 , p. 1840-1848 9 p.

Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG

van der Poel C.E., Karssemeijer R.A., Boross P., van der Linden J.A., Blokland - Fromme M., van de Winkel J.G.J., Leusen J.H.W. 9 Dec 2010, In: Blood. 116 , p. 5327-5333 7 p.

In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling

de Haij S., Jansen J.H.M., Boross P., Beurskens F.J., Bakema J.E., Bos D.L., Martens A.C.M., Verbeek J.S., Parren P.W.H.I., van de Winkel J.G.J., Leusen J.H.W. 2010, In: Cancer Research. 70 , p. 3209-3217 9 p.

c-Jun activating binding protein 1 binds to the IgA receptor and modulates protein levels of FcalphaRI and FcRgamma-chain

Bakema J.E., Hiemstra I.H., Bakker J., de Haij S., Kok Y., Adema G.J., van Egmond M., Coffer P.J, van de Winkel J.G.J., Leusen J.H.W. 2010, In: European Journal of Immunology. 40 , p. 2035-2040 6 p.

Rapid production of recombinant human IgG With improved ADCC effector function in a transient expression system

van Berkel P.H.C., Gerritsen J., van Voskuilen E., Perdok G., Vink T., van de Winkel J.G.J., Parren P.W.H.I. 2010, In: Biotechnology and Bioengineering. 105 , p. 350-357 8 p.

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20 low expressing tumor cells that resist rituximab-mediated lysis.

van Meerten T., Rozemuller H., Hol S., Moerer P., Zwart M.C., Hagenbeek A., Mackus W.J.M., Parren P.W.H.I., van de Winkel J.G.J., Ebeling S.B., Martens A.C.M. 2010, In: Haematologica. 95 , p. 2063-2071 9 p.

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not